Search
Merbromin
go.drugbank.com/drugs/DB13392InvestigationalIt is an organomercuric disodium salt compound and a fluorescein that is available in many countries, except Switzerland, France, Germany, and the United States where the drug was withdrawn from market
SYNB1353
go.drugbank.com/drugs/DB17666InvestigationalSYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug. … It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]
IMM-101
go.drugbank.com/drugs/DB15850InvestigationalAs of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over … 1500 participants to evaluate the vaccine’s protective effects on cancer patients from severe COVID-19 infection (NCT04442048).
Bifenthrin
go.drugbank.com/drugs/DB15056ExperimentalBifenthrin is under investigation in clinical trial NCT01560247 (Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry).
Atamparib
go.drugbank.com/drugs/DB19028InvestigationalAtamparib is under investigation in clinical trial NCT05127590 (RBN-2397 in Combination With Pembrolizumab in Patients With SCCL).
CYNK-001
go.drugbank.com/drugs/DB15722InvestigationalCYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Azlocillin
go.drugbank.com/drugs/DB01061ApprovedAzlocillin is a semisynthetic ampicillin-derived acylureido penicillin.
Sulfisoxazole
go.drugbank.com/drugs/DB00263ApprovedVet approvedA short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
Synonyms: N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamide, 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamideAbdavomeran
go.drugbank.com/drugs/DB15695Investigational[L15012] BNT162b1 is undergoing further evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701). … [L15007, L15012] Early results from a phase 1/2 study in 45 healthy adult volunteers demonstrated RBD-binding immunoglobulin levels and 50% serum neutralizing titers higher than those observed in [COVID
Necuparanib
go.drugbank.com/drugs/DB16251InvestigationalNecuparanib is under investigation in clinical trial NCT01621243 (M402 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer).